Figure 1: Median Percentage Reduction From Baseline in 28-Day Frequency of FIAS and
Median Percentage Reduction From Baseline in 28-Day Frequency of FIAS and TCS by Time Point, Patients With FIAS and/or TCS at Baseline
Format
PNG
Source
Zynerba Pharmaceuticals, Inc.